



UNIVERSITAT DE
BARCELONA


Efectividad del concentrado de fibrinógeno en pacientes traumáticos con hemorragia crítica

Celia González Guerrero

ADVERTIMENT. La consulta d'aquesta tesi queda condicionada a l'acceptació de les següents condicions d'ús: La difusió d'aquesta tesi per mitjà del servei TDX (www.tdx.cat) i a través del Dipòsit Digital de la UB (diposit.ub.edu) ha estat autoritzada pels titulars dels drets de propietat intel·lectual únicament per a usos privats emmarcats en activitats d'investigació i docència. No s'autoritza la seva reproducció amb finalitats de lucre ni la seva difusió i posada a disposició des d'un lloc aliè al servei TDX ni al Dipòsit Digital de la UB. No s'autoritza la presentació del seu contingut en una finestra o marc aliè a TDX o al Dipòsit Digital de la UB (framing). Aquesta reserva de drets afecta tant al resum de presentació de la tesi com als seus continguts. En la utilització o cita de parts de la tesi és obligat indicar el nom de la persona autora.

ADVERTENCIA. La consulta de esta tesis queda condicionada a la aceptación de las siguientes condiciones de uso: La difusión de esta tesis por medio del servicio TDR (www.tdx.cat) y a través del Repositorio Digital de la UB (diposit.ub.edu) ha sido autorizada por los titulares de los derechos de propiedad intelectual únicamente para usos privados enmarcados en actividades de investigación y docencia. No se autoriza su reproducción con finalidades de lucro ni su difusión y puesta a disposición desde un sitio ajeno al servicio TDR o al Repositorio Digital de la UB. No se autoriza la presentación de su contenido en una ventana o marco ajeno a TDR o al Repositorio Digital de la UB (framing). Esta reserva de derechos afecta tanto al resumen de presentación de la tesis como a sus contenidos. En la utilización o cita de partes de la tesis es obligado indicar el nombre de la persona autora.

WARNING. On having consulted this thesis you're accepting the following use conditions: Spreading this thesis by the TDX (www.tdx.cat) service and by the UB Digital Repository (diposit.ub.edu) has been authorized by the titular of the intellectual property rights only for private uses placed in investigation and teaching activities. Reproduction with lucrative aims is not authorized nor its spreading and availability from a site foreign to the TDX service or to the UB Digital Repository. Introducing its content in a window or frame foreign to the TDX service or to the UB Digital Repository is not authorized (framing). Those rights affect to the presentation summary of the thesis as well as to its contents. In the using or citation of parts of the thesis it's obliged to indicate the name of the author.



USE OF HUMAN PROTHROMBIN COMPLEX CONCENTRATE AND HUMAN FIBRINOGEN CONCENTRATE ADMINISTRATION TO PATIENTS WITH HIGH-RISK OF SEVERE BLEEDING IN A TRAUMA HOSPITAL

González-Guerrero, C., Mestre Galofré, L., Brandariz Nuñez, D., Juárez, J.C., Lalueza, P., Girona, L., Montoro, J.B.
¹Pharmacy Unit. Hospital Universitari Vall d'Hebron. Barcelona. Spain

Background

Deficiency in prothrombin complex concentrates (PCC) and fibrinogen is a cause of massive haemorrhage whose correct management in emergency situations is controversial.

Methods

Retrospective observational study in a Trauma hospital. Patients with a documented life-threatening haemorrhage who received a PCC or fibrinogen prescription were included in the protocol, during a follow-up period of 6 months. Demographic data, treatment indication, INR (International Normalized Ratio) before and after treatment, admission diagnosis, PCC (II, VII, IX and X factors), fibrinogen dose, current oral anticoagulants (OAT) treatment, as well as data on administration of vitamin K, tranexamic acid or other hemoderivatives (red cells, platelets, plasma) was collected.

Results

A total of 18 patients were included in the study: 9 with PCC, 5 with fibrinogen, and 4 with both drugs. 60% and 71% of patients treated with PCC and fibrinogen, respectively, were women. Patient's mean age was 52 (range 18-90) for PCC and 58.12 (range 33-81) for fibrinogen.

- 20% of the patients who received PCC were being treated with oral anticoagulants (OAT) prior to the emergency bleeding.
- 64.71% had a politraumatism, and 82.35% were under surgical procedures when the PCC or fibrinogen was administered.

MEAN INR OF ALL PCC PATIENTS:

- **PRIOR:** 1.73 (SD 0.60).
- **AFTER:** 1,35 (SD 0,15)
- **MEAN DOSE:** 1680 UI (600 - 2400 UI). Being the dose referred to the IX factor.

MEAN INR OF OAT PATIENTS WITH PCC (20%):

- **PRIOR:** 2,60 (SD 0,40)
- **AFTER:** 1,31 (SD 0,05)

None of the anticoagulated patients were treated with fibrinogen.

FIBRINOGEN:


- **PRIOR:** fibrinogen mean levels were 1.95 (SD 1.18)
- **AFTER:** fibrinogen mean levels were 2,53 SD (1,04)
- **MEAN DOSE:** 2,38g. (1 - 4g.)
- **BIOLOGIC RECUPERATION:** 131.4 % (45 - 240 %). 1gr of fibrinogen causes an average increase of 0.47 g / L in fibrinogen plasma concentration.

Survival after seven days was:


- **For PCC:**
Anticoagulated: 50% (2patients)
Non-anticoagulated:100% (8 patients)
- **For fibrinogen: 87,5% (8 patients)**

Objective

To ascertain how PCC and fibrinogen are used in patients with life-threatening hemorrhagic disorders (trauma and surgery), especially in patients with underlying disease states that limit PCC synthesis or fibrinogen synthesis.



There is a estadistically significant difference between OAT and NON-OAT patients (p=0,001, t-student-Fisher)



Conclusions

- PCC treatment normalized INR among anticoagulated patients.
- Fibrinogen administration raised fibrinogen levels to the recommended serum levels range (according to the european guidelines).
- Consensus guidelines are needed for the appropriate therapeutic management of patients with severe bleeding.
- Clinical pharmacist should play an important role when managing patients with severe bleeding.

